[go: up one dir, main page]

WO2001068889A3 - Procede de transfection genique et de vaccination a travers la peau par electropermeabilisation - Google Patents

Procede de transfection genique et de vaccination a travers la peau par electropermeabilisation Download PDF

Info

Publication number
WO2001068889A3
WO2001068889A3 PCT/US2001/008502 US0108502W WO0168889A3 WO 2001068889 A3 WO2001068889 A3 WO 2001068889A3 US 0108502 W US0108502 W US 0108502W WO 0168889 A3 WO0168889 A3 WO 0168889A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
gene
polynucleotide
approach
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/008502
Other languages
English (en)
Other versions
WO2001068889A2 (fr
Inventor
Robert W Malone
Jill G Malone
Joseph J Drabick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2001250859A priority Critical patent/AU2001250859A1/en
Publication of WO2001068889A2 publication Critical patent/WO2001068889A2/fr
Publication of WO2001068889A3 publication Critical patent/WO2001068889A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des cellules de la peau ou du tissu des muqueuses d'un individu peuvent être transfectées avec un polynucléotide ou un gène au moyen de l'injection du polynucléotide dans la peau ou dans le tissu des muqueuses et de l'application d'un champ électrique pulsé au voisinage de l'injection. Cette approche est appropriée pour vacciner un individu contre le polypeptide exprimé, ceci produisant des anticorps ou une immunité induite par les cellules. Par exemple, des anticorps produits contre le produit d'expression d'un gène cloné à partir de banques de génomes ou d'ADNc peuvent être utilisés pour caractériser le produit et, ainsi, faire ressortir la fonction du gène. Cette approche peut également être employée chez l'animal ou chez l'homme pour traiter une pathologie ou pour modifier une condition de la peau qui affecte l'aspect de la peau. Des trousses permettant de mettre en oeuvre les procédés selon l'invention sont également présentées.
PCT/US2001/008502 2000-03-16 2001-03-16 Procede de transfection genique et de vaccination a travers la peau par electropermeabilisation Ceased WO2001068889A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001250859A AU2001250859A1 (en) 2000-03-16 2001-03-16 Method for gene transfection and vaccination through skin using electropermeabilization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18984700A 2000-03-16 2000-03-16
US60/189,847 2000-03-16

Publications (2)

Publication Number Publication Date
WO2001068889A2 WO2001068889A2 (fr) 2001-09-20
WO2001068889A3 true WO2001068889A3 (fr) 2002-04-25

Family

ID=37488067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008502 Ceased WO2001068889A2 (fr) 2000-03-16 2001-03-16 Procede de transfection genique et de vaccination a travers la peau par electropermeabilisation

Country Status (2)

Country Link
AU (1) AU2001250859A1 (fr)
WO (1) WO2001068889A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224008A3 (fr) 2005-05-12 2010-12-01 Murdoch University Gènes et protéines de brachyspira hyodysenteriae et leur utilisation en diagnostic et thérapie
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
JP2010535030A (ja) 2007-08-03 2010-11-18 スピロジーン ピーティーワイ エルティーディー ブラキスピラ・ヒオディセンテリアの新規な遺伝子とタンパク質及びその使用
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2363407A1 (fr) 2008-02-28 2011-09-07 Murdoch University Nouvelles séquences de Brachyspira, compositions immunogènes, procédés pour leur préparation et utilisation
WO2009117773A1 (fr) 2008-03-27 2009-10-01 Murdoch University Nouvelles séquences de brachyspira, compositions immunogènes, leurs procédés de fabrication et d'utilisation
ITCO20080016A1 (it) * 2008-04-22 2009-10-23 Giuseppe Caccia Manipolo per elettroporazione di prodotti farmacologici e/o naturali e/o estetici su strati cutanei a spessore contenuto

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
WO1991018103A1 (fr) * 1990-05-16 1991-11-28 Scientific Equipment Design & Development S.C. Procede et dispositif de permeabilisation de cellules vivantes
WO1996039531A1 (fr) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Administration de nucleotides a des organismes par electroporation
WO1997007826A1 (fr) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. Electroporation in vivo de cellules
WO1999064615A1 (fr) * 1998-06-08 1999-12-16 Valentis, Inc. Formulations pour electroporation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5019034B1 (en) * 1988-01-21 1995-08-15 Massachusetts Inst Technology Control of transport of molecules across tissue using electroporation
WO1991018103A1 (fr) * 1990-05-16 1991-11-28 Scientific Equipment Design & Development S.C. Procede et dispositif de permeabilisation de cellules vivantes
WO1996039531A1 (fr) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Administration de nucleotides a des organismes par electroporation
WO1997007826A1 (fr) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. Electroporation in vivo de cellules
WO1999064615A1 (fr) * 1998-06-08 1999-12-16 Valentis, Inc. Formulations pour electroporation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BANGA A K ET AL: "Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 16, no. 10, 1 October 1998 (1998-10-01), pages 408 - 412, XP004145647, ISSN: 0167-7799 *
BARON S ET AL: "Electroporation of antibodies, DNA, and other macromolecules into cells: a highly efficient method", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 242, no. 1-2, 28 August 2000 (2000-08-28), pages 115 - 126, XP004210715, ISSN: 0022-1759 *
JOSEPH J. DRABICK ET AL: "Cutaneous Transfection and Immune Responses to Intradermal Nucleic Acid accination Are Significantly Enhanced by in Vivo Electropermeabilization", MOLECULAR THERAPY, vol. 3, no. 2, February 2001 (2001-02-01), pages 249 - 255, XP002190195 *
SELBY M ET AL: "Enhancement of DNA vaccine potency by electroporation in vivo", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 83, no. 1-2, 29 September 2000 (2000-09-29), pages 147 - 152, XP004212162, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
WO2001068889A2 (fr) 2001-09-20
AU2001250859A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
Langevin et al. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture
Cabelguen et al. Bimodal locomotion elicited by electrical stimulation of the midbrain in the salamander Notophthalmus viridescens
EP0472712A4 (en) Novel sequences preferentially expressed in early seed development and methods related thereto
ATE185083T1 (de) Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation
WO1995027044A1 (fr) VECTEURS D'ADNc D'ALPHAVIRUS
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
ATE235558T1 (de) Transformation von tierischen somatischen zellen mittels partikeln
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
NO960309L (no) Agonister og antagonister for humaninterleukin-10
WO2001068889A3 (fr) Procede de transfection genique et de vaccination a travers la peau par electropermeabilisation
PT1699480E (pt) AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
WO2001068828A3 (fr) Compositions et methodes destinees a l'expression regulee d'une proteine dans l'intestin
AU2003246537A1 (en) Device for needle-free injection of a medium into the tissue of a human or an animal, device for needle free production of an injection channel and method for the needle free injection of a medium in the tissue
KR102628416B1 (ko) 모발 성장 자극
KR101713061B1 (ko) 입 주위 근육 강화기구
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
DE69939212D1 (de) Polypeptid mit aktivität gegen das humane immundefizienz virus, dafür kodierende gene und verfahren zur herstellung des polypeptids
US20110123970A1 (en) Taxidermy flesh removal system and method
JPWO2006120767A1 (ja) ハンドトリートメント用のスパ装置、及びハンドトリートメントのためのスパ方法
EP1151756A4 (fr) Utilisation d'un gel polyacrilamide pour former une capsule dans un tissu d'un mammalien, procede de culture de cellules et procede de traitement des maladies oncologiques et du diabete sucre
WO2002068629A3 (fr) Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions
WO1999045116A3 (fr) Homologue humain d'un gene de migration nucleaire et son utilisation
CN1293038A (zh) 一种新的医学、美容和化妆品用组合物及其应用
HK1044568A1 (zh) 一种治疗剂的应激应答性诱导及其使用方法
WO2004083364A3 (fr) Preparation cellulaire et son utilisation pour traiter les articulations et les defauts de cartilage, et procede de fabrication associe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP